Natera, Inc. $NTRA Shares Acquired by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 36.9% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 43,550 shares of the medical research company’s stock after buying an additional 11,750 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Natera were worth $8,710,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of NTRA. Robinhood Asset Management LLC acquired a new stake in shares of Natera during the fourth quarter worth $12,981,000. Systrade AG acquired a new position in Natera in the fourth quarter valued at $11,454,000. Quantbot Technologies LP acquired a new position in Natera in the third quarter valued at $1,069,000. J. Safra Sarasin Holding AG purchased a new position in Natera during the fourth quarter worth about $2,825,000. Finally, Meridiem Capital Partners LP purchased a new position in Natera during the third quarter worth about $11,900,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Performance

Shares of Natera stock opened at $279.32 on Friday. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $279.63. The stock has a market capitalization of $40.00 billion, a P/E ratio of -171.36 and a beta of 1.51. The business’s fifty day moving average price is $219.79 and its 200 day moving average price is $217.32.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 3,405 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45. Following the completion of the sale, the insider owned 142,295 shares in the company, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the sale, the director directly owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 175,872 shares of company stock worth $38,808,996. Corporate insiders own 5.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on NTRA. UBS Group set a $260.00 price target on Natera in a report on Wednesday, June 24th. Robert W. Baird set a $265.00 price objective on shares of Natera in a report on Friday, May 8th. Sanford C. Bernstein started coverage on shares of Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 target price on the stock. Wolfe Research began coverage on shares of Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Finally, BTIG Research set a $275.00 target price on shares of Natera and gave the company a “buy” rating in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $260.33.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.